<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088605</url>
  </required_header>
  <id_info>
    <org_study_id>TOP1630-TV-04</org_study_id>
    <nct_id>NCT03088605</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TOP1630 for Dry Eye Syndrome</brief_title>
  <official_title>A Single-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of TOP1630 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topivert Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topivert Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In subjects with Dry Eye Syndrome:&#xD;
&#xD;
      The primary objective of this study is to compare the safety and tolerability of TOP1630&#xD;
      Ophthalmic Solution to placebo.&#xD;
&#xD;
      The secondary objectives are to compare the efficacy of TOP1630 Ophthalmic Solution to&#xD;
      placebo for the treatment of the signs and symptoms of dry eye syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to assess the safety, tolerability and efficacy of TOP1630 ophthalmic&#xD;
      solution in subjects with Dry Eye Syndrome.&#xD;
&#xD;
      Eligible subjects will be randomized double masked to either TOP1630 or placebo.&#xD;
&#xD;
      Part 1 (time frame 12 days) comprises assessment of safety, tolerability and ocular comfort.&#xD;
&#xD;
      Part 2 (time frame 35 days) comprises assessment of safety, tolerability and efficacy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2017</start_date>
  <completion_date type="Actual">June 15, 2017</completion_date>
  <primary_completion_date type="Actual">June 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Part 1: 12 days time frame; Part 2: 35 days time frame</time_frame>
    <description>Visual Acuity will be measured using the EDTRS chart to assess changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit-lamp Biomicroscopy</measure>
    <time_frame>Part 1: 12 days time frame; Part 2: 35 days time frame</time_frame>
    <description>Slit lamp biomicroscopy exams will be performed to assess any changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Part 1: 12 days time frame; Part 2: 35 days time frame</time_frame>
    <description>Blood Pressure, Pulse and SPo2 will be performed to assess changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drop Comfort Assessment</measure>
    <time_frame>Part 1: 12 days time frame</time_frame>
    <description>The comfort of the eye drop will be performed to assess changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Part 1: 12 days time frame; Part 2: 35 days time frame</time_frame>
    <description>a non-contact tonometer will be used to perform IOP to assess changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal sensitivity</measure>
    <time_frame>Part 1: 12 days time frame; Part 2: 35 days time frame</time_frame>
    <description>The aesthesiometer will be used to perform corneal sensitivity to assess changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Undilated Fundoscopy</measure>
    <time_frame>Part 2: 35 days time frame</time_frame>
    <description>Non-Contact undilated fundoscopy exam will be performed to assess changes from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Part 1: 12 days time frame; Part 2: 35 days time frame</time_frame>
    <description>Adverse event questioning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular discomfort</measure>
    <time_frame>Part 2: 35 days time frame</time_frame>
    <description>Ocular discomfort severity assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry eye symptoms</measure>
    <time_frame>Part 2: 35 days time frame</time_frame>
    <description>Dry eye syndrome symptom assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry eye signs</measure>
    <time_frame>Part 2: 35 days time frame</time_frame>
    <description>Dry eye syndrome conjunctival staining assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear film break up time</measure>
    <time_frame>Part 2: 35 days time frame</time_frame>
    <description>Tear film break up time measured after instillation of sodium fluorescein solution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer's test</measure>
    <time_frame>Part 2: 35 days time frame</time_frame>
    <description>Measurement of Schirmer test strips</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impression cytology</measure>
    <time_frame>Part 2: 35 days time frame</time_frame>
    <description>Impression cytology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily symptom assessment</measure>
    <time_frame>Part 2: 35 days time frame</time_frame>
    <description>Daily symptom assessment using diary cards</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TOP1630 Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Vehicle) Ophthalmic Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOP1630 Ophthalmic Solution</intervention_name>
    <description>Bilateral ocular drug administration</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to TOP1630 Ophthalmic Solution</intervention_name>
    <description>Bilateral ocular drug administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age;&#xD;
&#xD;
          -  Provide written informed consent;&#xD;
&#xD;
          -  Have a reported history of dry eye;&#xD;
&#xD;
          -  Have a history of use of eye drops for dry eye symptoms;&#xD;
&#xD;
        Additionally for Part 2&#xD;
&#xD;
        Symptoms of dry eye syndrome including:&#xD;
&#xD;
          -  Ocular discomfort&#xD;
&#xD;
          -  Conjunctival redness&#xD;
&#xD;
          -  Tear film break up time&#xD;
&#xD;
          -  Schirmer test score&#xD;
&#xD;
        Signs of dry eye syndrome including:&#xD;
&#xD;
        Conjunctival staining score&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any clinically significant slit lamp findings at entry visit ;&#xD;
&#xD;
          -  Be diagnosed with an ongoing ocular infection;&#xD;
&#xD;
          -  Have any significant ocular lesion that could interfere with assessment of safety or&#xD;
             efficacy or prevent study conduct in the opinion of the PI;&#xD;
&#xD;
          -  Have any planned ocular and/or lid surgeries over the study period;&#xD;
&#xD;
          -  Have an uncontrolled systemic disease;&#xD;
&#xD;
          -  Be a woman who is pregnant, nursing or planning a pregnancy;&#xD;
&#xD;
          -  Be a woman of childbearing potential who is not using an acceptable means of birth&#xD;
             control;&#xD;
&#xD;
          -  Have a known allergy and/or sensitivity to the test article or its components;&#xD;
&#xD;
          -  Have a condition or be in a situation which the investigator feels may put the subject&#xD;
             at significant risk, may confound the study results, or may interfere significantly&#xD;
             with the subject's participation in the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G Torkildsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Andover Eye Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <disposition_first_submitted>September 21, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>September 21, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 26, 2018</disposition_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 21, 2020</submitted>
    <submission_canceled>January 28, 2020</submission_canceled>
    <submitted>February 6, 2020</submitted>
    <returned>February 19, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

